Clinical Trials Logo

Clinical Trial Summary

This trial will evaluate the impact of an integrated intervention of daily maternal calcium, aspirin, and multiple micronutrients (CAMMS) compared to iron-folic acid (IFA) during pregnancy on preterm birth and other adverse birth outcomes. Both interventions will be delivered through existing antenatal service platforms using context-specific strategies informed by formative research incorporating human-centered design processes to achieve high acceptability and high adherence, in three low-income countries with diverse contexts: Burkina Faso, Pakistan, and Zimbabwe.


Clinical Trial Description

The CAMMS trial is an individually randomized, unblinded, phase III trial comparing aspirin, calcium and multiple micronutrients (intervention) versus iron-folic acid (control) among 10,000 pregnant women. The primary outcome is total preterm birth, stratified by spontaneous and indicated. Eligible pregnant women will be enrolled from antenatal clinics in three study populations in Burkina Faso, Pakistan, and Zimbabwe following written informed consent. All women attending antenatal care (ANC) who are positive on a urine pregnancy test and have a fetal ultrasound examination confirming fetal heartbeat, intrauterine pregnancy, and gestational age 6<20 weeks' will be eligible for enrollment. Women who are <6 weeks will be rescheduled for 2-3 weeks later. Baseline data and clinical assessments will be conducted, and women will be randomized to daily ingestion of CAMMS or IFA until delivery. In Burkina Faso, for women randomized to CAMMS, the aspirin will be withheld until 13 weeks' gestation when it can be initiated concurrently with sulfadoxine-pyrimethamine. Women will receive context-specific adherence promotion interventions designed during formative research incorporating Human-Centered Design (HCD) processes in each country. Mothers will be followed up at 4-weekly intervals throughout pregnancy plus an additional study contact (by visit, phone call, WhatsApp, or text message) at 1-2 weeks after starting the study drug to check for tolerance and adherence. Women may also be seen at closer intervals in the third trimester by the Ministry of Health clinics. Women will be encouraged to deliver in a health institution. Between baseline and delivery, research procedures will be undertaken by research staff based at antenatal clinics during mothers' routine antenatal visits to reduce time burden on participants. Depending on gestational age at recruitment, women will receive 7-11 research visits. One additional visit or contact by text-message (SMS) or phone call will occur one-two weeks after randomization to check that the women is tolerating and correctly taking the interventions. At delivery, infant weight and gestational age will be measured/determined by research staff based at delivery clinics or, for home deliveries, during home visits conducted within 72 hours of delivery. For infants born outside the study area or who are not reached by research staff within 72 hours, date of birth and birth weight will be transcribed from the infant's health record with source of information noted. In unusual situations where the mother and infant cannot be reached in person before 180 days postpartum but can be reached by telephone, WhatsApp, or Text message, maternal report of data of birth and birth weight will be recorded with the source of information noted. For all infants reached by a research staff member within 72 hours of birth, birth length and head circumference will be measured by standardized research staff with high quality equipment (length measured to nearest 0.1cm with infant length board and Shorr insert-tape (Weigh & Measure LLC., Olney, MD, USA). Mothers and infants will be followed to 42 days post-partum for vital status and post-partum maternal Adverse Events (AEs) and Serious Adverse Events (SAEs). This visit may be conducted in person, by telephone, WhatsApp or text message with the source of information recorded. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05612984
Study type Interventional
Source Johns Hopkins Bloomberg School of Public Health
Contact
Status Withdrawn
Phase Phase 3
Start date April 1, 2024
Completion date December 31, 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT06168149 - The Relationship of Fetal Lung Elastography Values With the Development of Respiratory Distress in Cases of Preterm Labor
Completed NCT02538718 - Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor N/A
Not yet recruiting NCT05864066 - Cyclin-dependent Kinase Inhibitor 2A (Placental Senescence Marker) on Labor-related Signals
Terminated NCT03715530 - Use of Placental Alpha Microglobulin-1(PAMG-1) to Diagnose Premature Rupture of Membranes in Pregnant Women N/A
Recruiting NCT03638037 - Correlation Between Maternal Vitamin D Level And Preterm Birth
Recruiting NCT03992534 - The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth Phase 1
Withdrawn NCT03122704 - Group B Streptococcus (GBS) Infection and in Preterm Labor Women Conceived Through IVF N/A
Completed NCT02536352 - Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being Early Phase 1
Recruiting NCT01518816 - Role of Serum Total Antioxidant Level in Preterm Labor N/A
Recruiting NCT04590677 - Prediction of the Onset of Term and Preterm Labour
Completed NCT03112018 - Strengthening Facility-based Intrapartum/Immediate Newborn Care to Reduce Mortality of Preterm Infants in Migori County, Kenya and Busoga Region, Uganda N/A
Active, not recruiting NCT04301518 - Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs N/A
Completed NCT03785795 - Multichannel EMG Diagnosing True Preterm Labor
Withdrawn NCT02351310 - Effectiveness of ACS in Extreme Preemies Phase 3
Not yet recruiting NCT01985594 - Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial Phase 2
Not yet recruiting NCT04532086 - Uterocervical Angle and Preterm Labour
Completed NCT04605172 - Lockdown Impact on Spontaneous Premature Birth in a Level III NICU
Recruiting NCT04417595 - Investigating N-3 Fatty Acids to Prevent Neonatal Tobacco-related outcomeS Phase 2
Completed NCT03923023 - Impact of the PREEMI Package on Neonatal Mortality
Recruiting NCT06157203 - Labor Status Monitor for Diagnosing True vs False Labor in Preterm Patients